BioWorld Asia

Dec. 14, 2005

BioAlliance Pharma Completes Initial Public Offering For EUR30M

PARIS - BioAlliance Pharma SA completed its initial public offering on Eurolist Compartment C of the Euronext stock exchange in Paris, raising gross proceeds of some €30 million (US$35.9 million). (BioWorld International) Read More

Domantis' Valuation Higher For £17M Third Financing

Dutch Team Finds Aspects Of Cell Cycle Checkpoints

Zealand Pharma Learning Lessons From Pulled IPO

Group Of GMO Crop Raiders Acquitted By French Court

Cellartis Brings In EUR 8M For Embryonic Stem Cell Work

Alizyme Reports Positive Data For Cetilistat, Plans Phase III

Other News To Note

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2025.

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 18, 2025.

3D representation of tumor microenvironment

EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment

BioWorld Science

Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...